PCM
PROK icon

Penserra Capital Management’s ProKidney PROK Stock Holding History

Penserra Capital Management’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,704
Closed -$26K – 1163
2022
Q2 		$26K Buy
2,704
+90
+3% +$890 ﹤0.01% 1059
2022
Q1 		$25K Buy
+2,614
New +$25.8K ﹤0.01% 1202

Other funds holding PROK

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Penserra Capital Management's PROK Position: Q3 2022 in Review

Penserra Capital Management sold out of ProKidney (PROK) in Q3 2022, closing a stake of 2,704 shares — an estimated $26K sold.

Penserra Capital Management first reported a position in PROK in Q1 2022 and held it in 2 quarters. The position peaked at $26K in Q2 2022. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

  • Penserra Capital Management reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 2,704 ProKidney shares in Q3 2022, an estimated $26K.
  • Penserra Capital Management first reported a position in ProKidney in Q1 2022 and held it in 2 quarters.
  • Penserra Capital Management's ProKidney position peaked at $26K in Q2 2022.
  • 18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.